Human — controlled trial

Growth hormone release by the novel GH releasing peptide hexarelin in patients with homozygous beta-thalassemia

Patients with beta-thalassemia often present with abnormalities in growth and other endocrine functions. Growth hormone (GH) secretion is controlled via somatostatin and growth hormone releasing hormone (GHRH). Recently, Hexarelin, a new potent GH secretagogue (His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), was synthesized. Our study was designed to assess and compare its efficacy as a GH secretagogue to GHRH 1-29 in beta-thalassemia. Eighteen patients, regularly transfused and c…

Cited by

Sermorelin
What the research on Sermorelin actually shows
The indexed literature on Sermorelin includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Sermorelin is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.

Compounds examined

Sermorelin

Study records state what a paper reported. PepIndex does not interpret findings, assess clinical significance, or restate results in language implying an application not present in the source. Last reviewed 23 Jul 2026.